Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 7.6% on Analyst Upgrade

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) shares traded up 7.6% during trading on Friday after Jefferies Financial Group upgraded the stock from a hold rating to a buy rating. Jefferies Financial Group now has a $21.00 price target on the stock, up from their previous price target of $10.00. Aurinia Pharmaceuticals traded as high as $15.27 and last traded at $15.0080. 453,793 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,648,158 shares. The stock had previously closed at $13.95.

A number of other brokerages have also weighed in on AUPH. Weiss Ratings restated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $15.00 price objective (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.67.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares in the last quarter. MAI Capital Management acquired a new stake in Aurinia Pharmaceuticals during the 1st quarter worth approximately $39,000. DekaBank Deutsche Girozentrale bought a new position in Aurinia Pharmaceuticals in the first quarter valued at approximately $60,000. Xponance Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $82,000. Finally, Kazazian Asset Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $84,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 6.8%

The firm has a market capitalization of $1.96 billion, a P/E ratio of 34.82 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The firm’s 50-day moving average is $12.22 and its 200 day moving average is $10.12.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $73.47 million during the quarter, compared to the consensus estimate of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.